UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 13, 2005
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
(Exact name of Registrant as specified in its charter)
Delaware 0-26224 51-0317849
(State or other jurisdiction of (Commission File Number) (I.R.S. Employer
incorporation or organization) Identification No.)
311 Enterprise Drive
Plainsboro, NJ 08536
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (609) 275-0500
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
ITEM 8.01. OTHER EVENTS.
On June 13, 2005, the United States Supreme Court vacated the June 2003 judgment
of the United States Court of Appeals for the Federal Circuit, which had
affirmed the judgment of the United States District Court for the Southern
District of California in the case of Integra LifeSciences I Ltd. and The
Burnham Institute v. Merck KGaA.
The Supreme Court held that the Court of Appeals applied an erroneous
interpretation of 35 U.S.C. ss.271(e)(1) when it rejected the challenge of Merck
KGaA to the jury's finding that Merck KGaA failed to show that its activities
were exempt from claims of patent infringement under that statute. On remand,
the Federal Circuit will review the evidence under a reasonableness test that
does not provide categorical exclusions of certain types of activities. As a
result, the trial court's judgment ordering Merck KgaA to pay Integra $6.4
million in damages could be overturned.
The Company has not recorded any gain in connection with this matter, pending
final resolution and completion of the appeals process.
A copy of the press release issued by the Company discussing the ruling is
attached as Exhibit 99.1 to this Current Report on Form 8-K.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.
(c) Exhibits.
Exhibit Number Description of Exhibit
------------------- ---------------------------
99.1 Press release issued June 13, 2005
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned, hereunto duly authorized.
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
Date: June 17, 2005 By: /s/ Stuart M. Essig
--------------------------
Stuart M. Essig
President and Chief Executive Officer
Exhibit Index
Exhibit Number Description of Exhibit
------------------- ---------------------------
99.1 Press release issued Press release issued June 13, 2005